Free stock market and financial news API
Instant access to global stock market and finance news also including funds, crypto and more along with comprehensive sentiment analysis.
{
"meta": {
"found": 3956,
"returned": 5,
"limit": 5,
"page": 1
},
"data": [
{
"uuid": "310c5c74-f51a-4c5f-8f51-b3dd1b276dc8",
"title": "Q3 2022 EPS Estimates for Sema4 Holdings Corp. (NASDAQ:SMFR) Cut by Analyst",
"description": "Read Q3 2022 EPS Estimates for Sema4 Holdings Corp. (NASDAQ:SMFR) Cut by Analyst at ETF Daily News",
"keywords": "Sema4, NASDAQ:SMFR, SMFR, Medical, Earnings Estimates, Jefferies Financial Group Inc.",
"snippet": "Sema4 Holdings Corp. (NASDAQ:SMFR – Get Rating) – Equities research analysts at Jefferies Financial Group decreased their Q3 2022 earnings per share (EPS) e...",
"url": "https://www.etfdailynews.com/2022/08/19/q3-2022-eps-estimates-for-sema4-holdings-corp-nasdaqsmfr-cut-by-analyst/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/sema4-holdings-corp-logo.png?v=20210727074556&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:47.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "SMFR",
"name": "Sema4 Holdings Corp.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 202.50165,
"sentiment_score": 0.197767,
"highlights": [
{
"highlight": "Sema4 Holdings Corp. (NASDAQ:SMFR – Get Rating) – Equities research analysts at Jefferies Financial Group decreased their Q3 2022 earnings per share (EPS) estimates for shares of Sema4 in a note issued to investors on Tuesday, August 16th. Jefferies Financial Group analyst B.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Get Sema4 alerts:\n\nA number of other equities research analysts also recently weighed in on SMFR. Cowen decreased their price target on shares of Sema4 from $13.00 to $5.00 in a research note on Monday, May 16th.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Sema4 Stock Performance\n\nInsider Buying and Selling\n\nSMFR opened at $1.29 on Thursday. The stock’s 50 day simple moving average is $1.64 and its 200-day simple moving average is $2.32. The company has a current ratio of 1.97, a quick ratio of 3.72 and a debt-to-equity ratio of 0.02.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Institutional Investors Weigh In On Sema4\n\nA number of hedge funds and other institutional investors have recently bought and sold shares of SMFR. Goldman Sachs Group Inc. grew its holdings in shares of Sema4 by 26.3% during the second quarter.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "About Sema4\n\n(Get Rating)\n\nSema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Q3 2022 EPS Estimates for Sema4 Holdings Corp. (NASDAQ:SMFR) Cut by Analyst",
"sentiment": -0.2732,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "704ea3a7-c80b-4380-aba2-a73b1217ac7f",
"title": "Q3 2022 EPS Estimates for Savara Inc (NASDAQ:SVRA) Increased by Analyst",
"description": "Read Q3 2022 EPS Estimates for Savara Inc (NASDAQ:SVRA) Increased by Analyst at ETF Daily News",
"keywords": "Savara, NASDAQ:SVRA, SVRA, Medical, Earnings Estimates, Jefferies Financial Group Inc.",
"snippet": "Savara Inc (NASDAQ:SVRA – Get Rating) – Equities researchers at Jefferies Financial Group raised their Q3 2022 earnings per share estimates for Savara in a ...",
"url": "https://www.etfdailynews.com/2022/08/19/q3-2022-eps-estimates-for-savara-inc-nasdaqsvra-increased-by-analyst/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/savara-inc-logo.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:47.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "SVRA",
"name": "Savara Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 154.93724,
"sentiment_score": 0.427278,
"highlights": [
{
"highlight": "Savara Inc (NASDAQ:SVRA – Get Rating) – Equities researchers at Jefferies Financial Group raised their Q3 2022 earnings per share estimates for Savara in a note issued to investors on Tuesday, August 16th. Jefferies Financial Group analyst S.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Get Savara alerts:\n\nSavara Trading Up 0.6 %\n\nSavara stock opened at $1.64 on Thursday. The stock has a market cap of $187.03 million, a PE ratio of -6.56 and a beta of 0.90. The company has a current ratio of 39.23, a quick ratio of 39.23 and a debt-to-equity ratio of 0.20.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Savara has a 52 week low of $1.02 and a 52 week high of $1.91.\n\nInstitutional Inflows and Outflows\n\nInsiders Place Their Bets\n\nA number of institutional investors and hedge funds have recently modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Savara by 6.9% in the second quarter.",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Millennium Management LLC grew its stake in shares of Savara by 12.3% during the 2nd quarter. Millennium Management LLC now owns 156,314 shares of the company’s stock valued at $238,000 after buying an additional 17,093 shares during the period. State Street Corp increased its holdings in shares of Savara by 12.4% during the 1st quarter.",
"sentiment": 0.8957,
"highlighted_in": "main_text"
},
{
"highlight": "Renaissance Technologies LLC raised its position in shares of Savara by 235.3% in the 2nd quarter. Renaissance Technologies LLC now owns 56,000 shares of the company’s stock worth $85,000 after buying an additional 39,300 shares during the period. Finally, Sio Capital Management LLC boosted its holdings in Savara by 19.6% in the second quarter.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "In other Savara news, Director David A. Ramsay bought 39,906 shares of the company’s stock in a transaction that occurred on Friday, June 17th. The stock was purchased at an average cost of $1.33 per share, for a total transaction of $53,074.98.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "About Savara\n\n(Get Rating)\n\nSavara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Stories\n\nReceive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Q3 2022 EPS Estimates for Savara Inc (NASDAQ:SVRA) Increased by Analyst",
"sentiment": 0.2732,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "bb13d7ca-51ba-40c2-91fd-0fa80d5d4d87",
"title": "Q3 2022 EPS Estimates for TEGNA Inc. (NYSE:TGNA) Reduced by Analyst",
"description": "Read Q3 2022 EPS Estimates for TEGNA Inc. (NYSE:TGNA) Reduced by Analyst at ETF Daily News",
"keywords": "TEGNA, NYSE:TGNA, TGNA, Consumer Discretionary, Earnings Estimates, Barrington Research",
"snippet": "TEGNA Inc. (NYSE:TGNA – Get Rating) – Stock analysts at Barrington Research dropped their Q3 2022 earnings per share estimates for shares of TEGNA in a rese...",
"url": "https://www.etfdailynews.com/2022/08/19/q3-2022-eps-estimates-for-tegna-inc-nysetgna-reduced-by-analyst/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/tegna-inc-logo.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:46.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "WFC",
"name": "Wells Fargo & Company",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 27.16698,
"sentiment_score": 0.4404,
"highlights": [
{
"highlight": "Wells Fargo & Company lowered shares of TEGNA from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $23.00 to $24.00 in a research note on Wednesday, May 4th. StockNews.com raised shares of TEGNA from a “hold” rating to a “buy” rating in a research note on Tuesday, August 9th.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TGNA",
"name": "TEGNA Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 155.84233,
"sentiment_score": 0.417136,
"highlights": [
{
"highlight": "TEGNA Inc. (NYSE:TGNA – Get Rating) – Stock analysts at Barrington Research dropped their Q3 2022 earnings per share estimates for shares of TEGNA in a research report issued to clients and investors on Tuesday, August 16th. Barrington Research analyst J.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Get TEGNA alerts:\n\nSeveral other research analysts have also commented on the stock. Wells Fargo & Company lowered shares of TEGNA from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $23.00 to $24.00 in a research note on Wednesday, May 4th.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "StockNews.com raised shares of TEGNA from a “hold” rating to a “buy” rating in a research note on Tuesday, August 9th. Finally, Huber Research raised shares of TEGNA from an “underweight” rating to an “overweight” rating in a research report on Monday, June 6th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "According to MarketBeat, TEGNA presently has an average rating of “Hold” and an average price target of $23.50.\n\nTEGNA Stock Performance\n\nNYSE TGNA opened at $21.82 on Thursday. The business’s 50 day moving average price is $20.87 and its 200-day moving average price is $21.54.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "TEGNA (NYSE:TGNA – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.63 by ($0.03). The company had revenue of $784.90 million for the quarter, compared to the consensus estimate of $800.78 million.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "TEGNA had a return on equity of 20.18% and a net margin of 16.94%. The company’s revenue was up 7.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.50 earnings per share.\n\nHedge Funds Weigh In On TEGNA\n\nA number of hedge funds have recently added to or reduced their stakes in the stock.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Heritage Financial Services LLC acquired a new stake in shares of TEGNA during the second quarter worth $26,000. Prospera Financial Services Inc acquired a new position in TEGNA in the 1st quarter worth approximately $29,000. Steward Financial Group LLC purchased a new position in TEGNA during the 1st quarter worth approximately $33,000.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Covestor Ltd acquired a new stake in TEGNA during the 4th quarter valued at approximately $34,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of TEGNA by 71.9% in the 2nd quarter.",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "About TEGNA\n\n(Get Rating)\n\nTEGNA Inc, a media company, provides broadcast advertising and marketing products and services for businesses. The company operates 47 television stations in 39 markets of the United States that produce local programming, such as news, sports, and entertainment.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Articles\n\nReceive News & Ratings for TEGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TEGNA and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Q3 2022 EPS Estimates for TEGNA Inc. (NYSE:TGNA) Reduced by Analyst",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "35ecd4b3-23ee-4094-97b9-1f2007446a34",
"title": "Q3 2022 EPS Estimates for Viridian Therapeutics, Inc. (NASDAQ:VRDN) Lifted by SVB Leerink",
"description": "Read Q3 2022 EPS Estimates for Viridian Therapeutics, Inc. (NASDAQ:VRDN) Lifted by SVB Leerink at ETF Daily News",
"keywords": "Viridian Therapeutics, NASDAQ:VRDN, VRDN, Medical, Earnings Estimates, SVB Leerink LLC",
"snippet": "Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) – SVB Leerink increased their Q3 2022 earnings estimates for shares of Viridian Therapeutics in a not...",
"url": "https://www.etfdailynews.com/2022/08/19/q3-2022-eps-estimates-for-viridian-therapeutics-inc-nasdaqvrdn-lifted-by-svb-leerink/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/viridian-therapeutics-inc-logo.jpg?v=20211005130103&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:41.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "AIG",
"name": "American International Group, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 18.543243,
"sentiment_score": 0.7351,
"highlights": [
{
"highlight": "American International Group Inc. acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $140,000. Finally, Alps Advisors Inc. bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $192,000.",
"sentiment": 0.7351,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AIG-PA",
"name": "American International Group, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 18.543247,
"sentiment_score": 0.7351,
"highlights": [
{
"highlight": "American International Group Inc. acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $140,000. Finally, Alps Advisors Inc. bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $192,000.",
"sentiment": 0.7351,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RY",
"name": "Royal Bank of Canada",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 24.79335,
"sentiment_score": 0.802,
"highlights": [
{
"highlight": "Royal Bank of Canada bought a new position in shares of Viridian Therapeutics in the first quarter valued at about $128,000. American International Group Inc. acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $140,000.",
"sentiment": 0.802,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0OAL.L",
"name": "American International Group, Inc.",
"exchange": "LSE",
"exchange_long": "London Stock Exchange",
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 18.543129,
"sentiment_score": 0.7351,
"highlights": [
{
"highlight": "American International Group Inc. acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $140,000. Finally, Alps Advisors Inc. bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $192,000.",
"sentiment": 0.7351,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0QKU.L",
"name": "Royal Bank of Canada",
"exchange": "LSE",
"exchange_long": "London Stock Exchange",
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 24.7929,
"sentiment_score": 0.802,
"highlights": [
{
"highlight": "Royal Bank of Canada bought a new position in shares of Viridian Therapeutics in the first quarter valued at about $128,000. American International Group Inc. acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $140,000.",
"sentiment": 0.802,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "db01cdf1-4f6b-4939-b85d-40dbd887571f",
"title": "Jefferies Financial Group Comments on SomaLogic, Inc.’s Q3 2022 Earnings (NASDAQ:SLGC)",
"description": "Read Jefferies Financial Group Comments on SomaLogic, Inc.’s Q3 2022 Earnings (NASDAQ:SLGC) at ETF Daily News",
"keywords": "SomaLogic, NASDAQ:SLGC, SLGC, Business Service, Earnings Estimates, Jefferies Financial Group Inc.",
"snippet": "SomaLogic, Inc. (NASDAQ:SLGC – Get Rating) – Jefferies Financial Group reduced their Q3 2022 EPS estimates for shares of SomaLogic in a research report issu...",
"url": "https://www.etfdailynews.com/2022/08/19/jefferies-financial-group-comments-on-somalogic-inc-s-q3-2022-earnings-nasdaqslgc/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/somalogic-inc-logo.png?v=20211203092007&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:47.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "PRU",
"name": "Prudential Financial, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 27.070011,
"sentiment_score": 0.6249,
"highlights": [
{
"highlight": "Finally, Prudential Financial Inc. purchased a new position in shares of SomaLogic in the second quarter valued at about $48,000. 58.65% of the stock is currently owned by hedge funds and other institutional investors.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "4c073aa9-bf44-489a-9b17-043595a0da71",
"title": "Wedbush Comments on Viridian Therapeutics, Inc.’s Q3 2022 Earnings (NASDAQ:VRDN)",
"description": "Read Wedbush Comments on Viridian Therapeutics, Inc.’s Q3 2022 Earnings (NASDAQ:VRDN) at ETF Daily News",
"keywords": "Viridian Therapeutics, NASDAQ:VRDN, VRDN, Medical, Earnings Estimates, Wedbush",
"snippet": "Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) – Research analysts at Wedbush cut their Q3 2022 EPS estimates for Viridian Therapeutics in a note is...",
"url": "https://www.etfdailynews.com/2022/08/19/wedbush-comments-on-viridian-therapeutics-inc-s-q3-2022-earnings-nasdaqvrdn/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/viridian-therapeutics-inc-logo.jpg?v=20211005130103&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:46.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "AIG",
"name": "American International Group, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 17.720615,
"sentiment_score": 0.7906,
"highlights": [
{
"highlight": "American International Group Inc. purchased a new position in shares of Viridian Therapeutics in the second quarter valued at $140,000. Finally, Gyon Technologies Capital Management LP acquired a new stake in Viridian Therapeutics during the 1st quarter valued at $225,000.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AIG-PA",
"name": "American International Group, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 17.720621,
"sentiment_score": 0.7906,
"highlights": [
{
"highlight": "American International Group Inc. purchased a new position in shares of Viridian Therapeutics in the second quarter valued at $140,000. Finally, Gyon Technologies Capital Management LP acquired a new stake in Viridian Therapeutics during the 1st quarter valued at $225,000.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RY",
"name": "Royal Bank of Canada",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 23.677647,
"sentiment_score": 0.802,
"highlights": [
{
"highlight": "Royal Bank of Canada acquired a new position in shares of Viridian Therapeutics during the first quarter worth $128,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Viridian Therapeutics in the second quarter valued at $128,000.",
"sentiment": 0.802,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0OAL.L",
"name": "American International Group, Inc.",
"exchange": "LSE",
"exchange_long": "London Stock Exchange",
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 17.72051,
"sentiment_score": 0.7906,
"highlights": [
{
"highlight": "American International Group Inc. purchased a new position in shares of Viridian Therapeutics in the second quarter valued at $140,000. Finally, Gyon Technologies Capital Management LP acquired a new stake in Viridian Therapeutics during the 1st quarter valued at $225,000.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0QKU.L",
"name": "Royal Bank of Canada",
"exchange": "LSE",
"exchange_long": "London Stock Exchange",
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 23.677227,
"sentiment_score": 0.802,
"highlights": [
{
"highlight": "Royal Bank of Canada acquired a new position in shares of Viridian Therapeutics during the first quarter worth $128,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Viridian Therapeutics in the second quarter valued at $128,000.",
"sentiment": 0.802,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "05ff79f4-b5a1-4d6f-bec0-19fd68d1d501",
"title": "Brokers Issue Forecasts for Talaris Therapeutics, Inc.’s Q3 2022 Earnings (NASDAQ:TALS)",
"description": "Read Brokers Issue Forecasts for Talaris Therapeutics, Inc.’s Q3 2022 Earnings (NASDAQ:TALS) at ETF Daily News",
"keywords": "Talaris Therapeutics, NASDAQ:TALS, TALS, Medical, Earnings Estimates, SVB Leerink LLC",
"snippet": "Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) – Stock analysts at SVB Leerink lifted their Q3 2022 earnings estimates for Talaris Therapeutics in a ...",
"url": "https://www.etfdailynews.com/2022/08/19/brokers-issue-forecasts-for-talaris-therapeutics-inc-s-q3-2022-earnings-nasdaqtals/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/generic-stocks.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:45.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "BLK",
"name": "BlackRock, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 20.043165,
"sentiment_score": 0.8519,
"highlights": [
{
"highlight": "BlackRock Inc. boosted its stake in Talaris Therapeutics by 1.6% during the 1st quarter. BlackRock Inc. now owns 2,433,914 shares of the company’s stock worth $23,950,000 after acquiring an additional 38,449 shares during the last quarter. State Street Corp boosted its stake in Talaris Therapeutics by 25.8% during the 2nd quarter.",
"sentiment": 0.8519,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0QZZ.L",
"name": "BlackRock, Inc.",
"exchange": "LSE",
"exchange_long": "London Stock Exchange",
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 20.042675,
"sentiment_score": 0.8519,
"highlights": [
{
"highlight": "BlackRock Inc. boosted its stake in Talaris Therapeutics by 1.6% during the 1st quarter. BlackRock Inc. now owns 2,433,914 shares of the company’s stock worth $23,950,000 after acquiring an additional 38,449 shares during the last quarter. State Street Corp boosted its stake in Talaris Therapeutics by 25.8% during the 2nd quarter.",
"sentiment": 0.8519,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "b54f4aff-288a-4384-9d26-c7b3f2b76f22",
"title": "Research Analysts Offer Predictions for urban-gro, Inc.’s Q3 2022 Earnings (NASDAQ:UGRO)",
"description": "Read Research Analysts Offer Predictions for urban-gro, Inc.’s Q3 2022 Earnings (NASDAQ:UGRO) at ETF Daily News",
"keywords": "urban-gro, NASDAQ:UGRO, UGRO, Industrial Product, Earnings Estimates, Small Cap Consu",
"snippet": "urban-gro, Inc. (NASDAQ:UGRO – Get Rating) – Research analysts at Small Cap Consu decreased their Q3 2022 earnings estimates for shares of urban-gro in a re...",
"url": "https://www.etfdailynews.com/2022/08/19/research-analysts-offer-predictions-for-urban-gro-inc-s-q3-2022-earnings-nasdaqugro/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/urban-gro-inc-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:45.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "UGRO",
"name": "urban-gro, Inc.",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 128.33409,
"sentiment_score": 0.33931,
"highlights": [
{
"highlight": "urban-gro, Inc. (NASDAQ:UGRO – Get Rating) – Research analysts at Small Cap Consu decreased their Q3 2022 earnings estimates for shares of urban-gro in a research report issued on Tuesday, August 16th. Small Cap Consu analyst E.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Get urban-gro alerts:\n\nA number of other equities research analysts have also commented on UGRO. Craig Hallum initiated coverage on urban-gro in a research report on Monday, May 2nd. They set a “buy” rating for the company.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Maxim Group decreased their price target on shares of urban-gro from $20.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday.\n\nurban-gro Stock Down 4.1 %\n\nInstitutional Trading of urban-gro\n\nShares of urban-gro stock opened at $4.45 on Thursday.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "The stock has a market cap of $47.33 million, a PE ratio of -14.83 and a beta of 2.39. urban-gro has a 12 month low of $4.31 and a 12 month high of $17.30. The business has a fifty day simple moving average of $5.56 and a 200-day simple moving average of $7.56.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Jane Street Group LLC acquired a new position in urban-gro in the 1st quarter worth about $108,000. Bank of America Corp DE increased its holdings in urban-gro by 128.8% in the first quarter. Bank of America Corp DE now owns 18,302 shares of the company’s stock worth $197,000 after buying an additional 10,302 shares during the last quarter.",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "State Street Corp raised its position in urban-gro by 13.1% during the first quarter. State Street Corp now owns 21,595 shares of the company’s stock valued at $232,000 after acquiring an additional 2,495 shares in the last quarter. Vident Investment Advisory LLC lifted its stake in urban-gro by 69.1% in the first quarter.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Davy Global Fund Management Ltd grew its position in urban-gro by 43.4% in the first quarter.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About urban-gro\n\n(Get Rating)\n\nurban-gro, Inc operates as an engineering design services company that integrates complex environmental equipment systems to create indoor cultivation facilities for the commercial horticulture market in the United States, Canada, and Europe.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Articles\n\nReceive News & Ratings for urban-gro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for urban-gro and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Research Analysts Offer Predictions for urban-gro, Inc.’s Q3 2022 Earnings (NASDAQ:UGRO)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "c0166fbc-e79a-45ce-b2b6-8efa272d5b04",
"title": "Coca-Cola HBC AG (LON:CCH) Insider Zoran Bogdanovic Purchases 204 Shares",
"description": "Read Coca-Cola HBC AG (LON:CCH) Insider Zoran Bogdanovic Purchases 204 Shares at ETF Daily News",
"keywords": "Coca-Cola HBC, LON:CCH, CCH, Consumer Defensive, Insider Trading, Insider Trades, Stocks",
"snippet": "Coca-Cola HBC AG (LON:CCH – Get Rating) insider Zoran Bogdanovic purchased 204 shares of the company’s stock in a transaction that occurred on Wednesday, Au...",
"url": "https://www.etfdailynews.com/2022/08/19/coca-cola-hbc-ag-loncch-insider-zoran-bogdanovic-purchases-204-shares/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/coca-cola-hbc-ag-logo.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:47.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "DB",
"name": "Deutsche Bank Aktiengesellschaft",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 30.474102,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Coca-Cola HBC from GBX 2,525 ($30.51) to GBX 2,600 ($31.42) and gave the stock a “buy” rating in a research note on Friday, August 12th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JPM",
"name": "JPMorgan Chase & Co.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 26.345684,
"sentiment_score": 0.5719,
"highlights": [
{
"highlight": "JPMorgan Chase & Co. reissued a “neutral” rating and set a GBX 1,900 ($22.96) price target on shares of Coca-Cola HBC in a research report on Friday, May 13th. Barclays boosted their price target on Coca-Cola HBC from GBX 1,825 ($22.05) to GBX 2,200 ($26.58) and gave the stock a “neutral” rating in a research note on Monday.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CCHGY",
"name": "Coca-Cola HBC AG",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 205.48889,
"sentiment_score": 0.45504,
"highlights": [
{
"highlight": "Coca-Cola HBC AG (LON:CCH – Get Rating) insider Zoran Bogdanovic purchased 204 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was purchased at an average price of GBX 2,065 ($24.95) per share, for a total transaction of £4,212.60 ($5,090.14).",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Zoran Bogdanovic also recently made the following trade(s):\n\nGet Coca-Cola HBC alerts:\n\nOn Monday, July 18th, Zoran Bogdanovic acquired 218 shares of Coca-Cola HBC stock. The shares were purchased at an average price of GBX 1,957 ($23.65) per share, with a total value of £4,266.26 ($5,154.98).",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "On Friday, June 17th, Zoran Bogdanovic bought 227 shares of Coca-Cola HBC stock. The stock was purchased at an average price of GBX 1,799 ($21.74) per share, for a total transaction of £4,083.73 ($4,934.42).\n\nCoca-Cola HBC Trading Up 1.6 %\n\nCoca-Cola HBC stock opened at GBX 2,084 ($25.18) on Friday.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Coca-Cola HBC AG has a 52-week low of GBX 1,403.50 ($16.96) and a 52-week high of GBX 2,706 ($32.70). The company has a market cap of £7.64 billion and a P/E ratio of 1,653.97. The company has a quick ratio of 0.80, a current ratio of 1.02 and a debt-to-equity ratio of 101.90.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast Growth\n\nAbout Coca-Cola HBC\n\nSeveral equities research analysts recently weighed in on CCH shares. JPMorgan Chase & Co. reissued a “neutral” rating and set a GBX 1,900 ($22.96) price target on shares of Coca-Cola HBC in a research report on Friday, May 13th.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Barclays boosted their price target on Coca-Cola HBC from GBX 1,825 ($22.05) to GBX 2,200 ($26.58) and gave the stock a “neutral” rating in a research note on Monday. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,000 ($24.17) price objective on shares of Coca-Cola HBC in a report on Thursday, June 16th.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "Morgan Stanley restated an “equal weight” rating on shares of Coca-Cola HBC in a research note on Wednesday, May 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Coca-Cola HBC from GBX 2,525 ($30.51) to GBX 2,600 ($31.42) and gave the stock a “buy” rating in a research note on Friday, August 12th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "According to MarketBeat.com, Coca-Cola HBC has a consensus rating of “Hold” and a consensus price target of GBX 2,080 ($25.13).\n\n(Get Rating)\n\nCoca-Cola HBC AG engages in the production, distribution, and sale of non-alcoholic ready-to-drink beverages worldwide.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Stories\n\nReceive News & Ratings for Coca-Cola HBC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coca-Cola HBC and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Coca-Cola HBC AG (LON:CCH) Insider Zoran Bogdanovic Purchases 204 Shares",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "CCHBF",
"name": "Coca-Cola HBC AG",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 205.48889,
"sentiment_score": 0.45504,
"highlights": [
{
"highlight": "Coca-Cola HBC AG (LON:CCH – Get Rating) insider Zoran Bogdanovic purchased 204 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was purchased at an average price of GBX 2,065 ($24.95) per share, for a total transaction of £4,212.60 ($5,090.14).",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Zoran Bogdanovic also recently made the following trade(s):\n\nGet Coca-Cola HBC alerts:\n\nOn Monday, July 18th, Zoran Bogdanovic acquired 218 shares of Coca-Cola HBC stock. The shares were purchased at an average price of GBX 1,957 ($23.65) per share, with a total value of £4,266.26 ($5,154.98).",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "On Friday, June 17th, Zoran Bogdanovic bought 227 shares of Coca-Cola HBC stock. The stock was purchased at an average price of GBX 1,799 ($21.74) per share, for a total transaction of £4,083.73 ($4,934.42).\n\nCoca-Cola HBC Trading Up 1.6 %\n\nCoca-Cola HBC stock opened at GBX 2,084 ($25.18) on Friday.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Coca-Cola HBC AG has a 52-week low of GBX 1,403.50 ($16.96) and a 52-week high of GBX 2,706 ($32.70). The company has a market cap of £7.64 billion and a P/E ratio of 1,653.97. The company has a quick ratio of 0.80, a current ratio of 1.02 and a debt-to-equity ratio of 101.90.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast Growth\n\nAbout Coca-Cola HBC\n\nSeveral equities research analysts recently weighed in on CCH shares. JPMorgan Chase & Co. reissued a “neutral” rating and set a GBX 1,900 ($22.96) price target on shares of Coca-Cola HBC in a research report on Friday, May 13th.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Barclays boosted their price target on Coca-Cola HBC from GBX 1,825 ($22.05) to GBX 2,200 ($26.58) and gave the stock a “neutral” rating in a research note on Monday. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,000 ($24.17) price objective on shares of Coca-Cola HBC in a report on Thursday, June 16th.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "Morgan Stanley restated an “equal weight” rating on shares of Coca-Cola HBC in a research note on Wednesday, May 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Coca-Cola HBC from GBX 2,525 ($30.51) to GBX 2,600 ($31.42) and gave the stock a “buy” rating in a research note on Friday, August 12th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "According to MarketBeat.com, Coca-Cola HBC has a consensus rating of “Hold” and a consensus price target of GBX 2,080 ($25.13).\n\n(Get Rating)\n\nCoca-Cola HBC AG engages in the production, distribution, and sale of non-alcoholic ready-to-drink beverages worldwide.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Stories\n\nReceive News & Ratings for Coca-Cola HBC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coca-Cola HBC and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Coca-Cola HBC AG (LON:CCH) Insider Zoran Bogdanovic Purchases 204 Shares",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "2a950cca-6129-4d6d-a1f1-7c1f2ab1db8c",
"title": "Johnson Matthey PLC (LON:JMAT) Insider Stephen Oxley Buys 15 Shares of Stock",
"description": "Read Johnson Matthey PLC (LON:JMAT) Insider Stephen Oxley Buys 15 Shares of Stock at ETF Daily News",
"keywords": "Johnson Matthey, LON:JMAT, JMAT, Basic Material, Insider Trading, Insider Trades, Stocks",
"snippet": "Johnson Matthey PLC (LON:JMAT – Get Rating) insider Stephen Oxley purchased 15 shares of Johnson Matthey stock in a transaction that occurred on Wednesday, Au...",
"url": "https://www.etfdailynews.com/2022/08/19/johnson-matthey-plc-lonjmat-insider-stephen-oxley-buys-15-shares-of-stock/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/johnson-matthey-plc-logo.png?v2&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:47.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "DB",
"name": "Deutsche Bank Aktiengesellschaft",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 29.669937,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Johnson Matthey from GBX 2,000 ($24.17) to GBX 2,300 ($27.79) and gave the stock a “hold” rating in a research note on Sunday, May 29th. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JMAT.L",
"name": "Johnson Matthey Plc",
"exchange": "LSE",
"exchange_long": "London Stock Exchange",
"country": "gb",
"type": "equity",
"industry": "Basic Materials",
"match_score": 140.67642,
"sentiment_score": 0.36897,
"highlights": [
{
"highlight": "Johnson Matthey PLC (LON:JMAT – Get Rating) insider Stephen Oxley purchased 15 shares of Johnson Matthey stock in a transaction that occurred on Wednesday, August 17th. The stock was acquired at an average price of GBX 2,219 ($26.81) per share, with a total value of £332.85 ($402.19).",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "Stephen Oxley also recently made the following trade(s):\n\nGet Johnson Matthey alerts:\n\nOn Wednesday, July 20th, Stephen Oxley acquired 18 shares of Johnson Matthey stock. The stock was acquired at an average price of GBX 2,133 ($25.77) per share, for a total transaction of £383.94 ($463.92).",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey Price Performance\n\nShares of LON JMAT opened at GBX 2,210 ($26.70) on Friday. The company’s fifty day moving average is GBX 2,060.83 and its two-hundred day moving average is GBX 2,003.70. The company has a debt-to-equity ratio of 51.33, a quick ratio of 0.68 and a current ratio of 1.33.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey PLC has a one year low of GBX 1,650 ($19.94) and a one year high of GBX 3,043 ($36.77).\n\nJohnson Matthey Increases Dividend\n\nAnalyst Upgrades and Downgrades\n\nThe business also recently declared a dividend, which was paid on Tuesday, August 2nd.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Berenberg Bank reissued a “buy” rating and set a GBX 2,550 ($30.81) price target on shares of Johnson Matthey in a report on Friday, May 27th. Barclays restated an “equal weight” rating and set a GBX 2,110 ($25.50) price target on shares of Johnson Matthey in a research note on Friday, May 27th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Morgan Stanley reiterated an “equal weight” rating on shares of Johnson Matthey in a research report on Wednesday, May 11th. Citigroup restated a “neutral” rating and set a GBX 2,200 ($26.58) price objective on shares of Johnson Matthey in a research report on Friday, August 12th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Johnson Matthey from GBX 2,000 ($24.17) to GBX 2,300 ($27.79) and gave the stock a “hold” rating in a research note on Sunday, May 29th. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Based on data from MarketBeat, Johnson Matthey has an average rating of “Hold” and a consensus target price of GBX 2,328.57 ($28.14).\n\nAbout Johnson Matthey\n\n(Get Rating)\n\nJohnson Matthey is a global leader in science that enables a cleaner and healthier world.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Stories\n\nReceive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey PLC (LON:JMAT) Insider Stephen Oxley Buys 15 Shares of Stock",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "JMPLF",
"name": "Johnson Matthey Plc",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Basic Materials",
"match_score": 140.65263,
"sentiment_score": 0.36897,
"highlights": [
{
"highlight": "Johnson Matthey PLC (LON:JMAT – Get Rating) insider Stephen Oxley purchased 15 shares of Johnson Matthey stock in a transaction that occurred on Wednesday, August 17th. The stock was acquired at an average price of GBX 2,219 ($26.81) per share, with a total value of £332.85 ($402.19).",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "Stephen Oxley also recently made the following trade(s):\n\nGet Johnson Matthey alerts:\n\nOn Wednesday, July 20th, Stephen Oxley acquired 18 shares of Johnson Matthey stock. The stock was acquired at an average price of GBX 2,133 ($25.77) per share, for a total transaction of £383.94 ($463.92).",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey Price Performance\n\nShares of LON JMAT opened at GBX 2,210 ($26.70) on Friday. The company’s fifty day moving average is GBX 2,060.83 and its two-hundred day moving average is GBX 2,003.70. The company has a debt-to-equity ratio of 51.33, a quick ratio of 0.68 and a current ratio of 1.33.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey PLC has a one year low of GBX 1,650 ($19.94) and a one year high of GBX 3,043 ($36.77).\n\nJohnson Matthey Increases Dividend\n\nAnalyst Upgrades and Downgrades\n\nThe business also recently declared a dividend, which was paid on Tuesday, August 2nd.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Berenberg Bank reissued a “buy” rating and set a GBX 2,550 ($30.81) price target on shares of Johnson Matthey in a report on Friday, May 27th. Barclays restated an “equal weight” rating and set a GBX 2,110 ($25.50) price target on shares of Johnson Matthey in a research note on Friday, May 27th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Morgan Stanley reiterated an “equal weight” rating on shares of Johnson Matthey in a research report on Wednesday, May 11th. Citigroup restated a “neutral” rating and set a GBX 2,200 ($26.58) price objective on shares of Johnson Matthey in a research report on Friday, August 12th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Johnson Matthey from GBX 2,000 ($24.17) to GBX 2,300 ($27.79) and gave the stock a “hold” rating in a research note on Sunday, May 29th. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Based on data from MarketBeat, Johnson Matthey has an average rating of “Hold” and a consensus target price of GBX 2,328.57 ($28.14).\n\nAbout Johnson Matthey\n\n(Get Rating)\n\nJohnson Matthey is a global leader in science that enables a cleaner and healthier world.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Stories\n\nReceive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey PLC (LON:JMAT) Insider Stephen Oxley Buys 15 Shares of Stock",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "JMPLY",
"name": "Johnson Matthey Plc",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Basic Materials",
"match_score": 140.65263,
"sentiment_score": 0.36897,
"highlights": [
{
"highlight": "Johnson Matthey PLC (LON:JMAT – Get Rating) insider Stephen Oxley purchased 15 shares of Johnson Matthey stock in a transaction that occurred on Wednesday, August 17th. The stock was acquired at an average price of GBX 2,219 ($26.81) per share, with a total value of £332.85 ($402.19).",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "Stephen Oxley also recently made the following trade(s):\n\nGet Johnson Matthey alerts:\n\nOn Wednesday, July 20th, Stephen Oxley acquired 18 shares of Johnson Matthey stock. The stock was acquired at an average price of GBX 2,133 ($25.77) per share, for a total transaction of £383.94 ($463.92).",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey Price Performance\n\nShares of LON JMAT opened at GBX 2,210 ($26.70) on Friday. The company’s fifty day moving average is GBX 2,060.83 and its two-hundred day moving average is GBX 2,003.70. The company has a debt-to-equity ratio of 51.33, a quick ratio of 0.68 and a current ratio of 1.33.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey PLC has a one year low of GBX 1,650 ($19.94) and a one year high of GBX 3,043 ($36.77).\n\nJohnson Matthey Increases Dividend\n\nAnalyst Upgrades and Downgrades\n\nThe business also recently declared a dividend, which was paid on Tuesday, August 2nd.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Berenberg Bank reissued a “buy” rating and set a GBX 2,550 ($30.81) price target on shares of Johnson Matthey in a report on Friday, May 27th. Barclays restated an “equal weight” rating and set a GBX 2,110 ($25.50) price target on shares of Johnson Matthey in a research note on Friday, May 27th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Morgan Stanley reiterated an “equal weight” rating on shares of Johnson Matthey in a research report on Wednesday, May 11th. Citigroup restated a “neutral” rating and set a GBX 2,200 ($26.58) price objective on shares of Johnson Matthey in a research report on Friday, August 12th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Johnson Matthey from GBX 2,000 ($24.17) to GBX 2,300 ($27.79) and gave the stock a “hold” rating in a research note on Sunday, May 29th. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Based on data from MarketBeat, Johnson Matthey has an average rating of “Hold” and a consensus target price of GBX 2,328.57 ($28.14).\n\nAbout Johnson Matthey\n\n(Get Rating)\n\nJohnson Matthey is a global leader in science that enables a cleaner and healthier world.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Stories\n\nReceive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson Matthey PLC (LON:JMAT) Insider Stephen Oxley Buys 15 Shares of Stock",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "bd67cb32-3bec-4005-a60a-e734202a000f",
"title": "Quantum-Si (NASDAQ:QSI) Shares Gap Up After Insider Buying Activity",
"description": "Read Quantum-Si (NASDAQ:QSI) Shares Gap Up After Insider Buying Activity at ETF Daily News",
"keywords": "Quantum-Si, NASDAQ:QSI, QSI, Computer and Technology, Stocks, Technicals",
"snippet": "Shares of Quantum-Si incorporated (NASDAQ:QSI – Get Rating) gapped up before the market opened on Thursday after an insider bought additional shares in the co...",
"url": "https://www.etfdailynews.com/2022/08/19/quantum-si-nasdaqqsi-shares-gap-up-after-insider-buying-activity/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/quantum-si-incorporated-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:06:42.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFG",
"name": "Principal Financial Group, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 29.247746,
"sentiment_score": 0.8176,
"highlights": [
{
"highlight": "Principal Financial Group Inc. increased its stake in Quantum-Si by 35.8% during the 2nd quarter. Principal Financial Group Inc. now owns 17,926 shares of the company’s stock worth $42,000 after buying an additional 4,730 shares during the period. ProShare Advisors LLC increased its stake in Quantum-Si by 60.6% during the 2nd quarter.",
"sentiment": 0.8176,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0KO5.L",
"name": "Principal Financial Group, Inc.",
"exchange": "LSE",
"exchange_long": "London Stock Exchange",
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 29.247337,
"sentiment_score": 0.8176,
"highlights": [
{
"highlight": "Principal Financial Group Inc. increased its stake in Quantum-Si by 35.8% during the 2nd quarter. Principal Financial Group Inc. now owns 17,926 shares of the company’s stock worth $42,000 after buying an additional 4,730 shares during the period. ProShare Advisors LLC increased its stake in Quantum-Si by 60.6% during the 2nd quarter.",
"sentiment": 0.8176,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "390c226f-3447-4566-b6f6-d0761891a027",
"title": "Ventyx Biosciences, Inc. to Post Q3 2022 Earnings of ($0.45) Per Share, Oppenheimer Forecasts (NASDAQ:VTYX)",
"description": "Read Ventyx Biosciences, Inc. to Post Q3 2022 Earnings of ($0.45) Per Share, Oppenheimer Forecasts (NASDAQ:VTYX) at ETF Daily News",
"keywords": "Ventyx Biosciences, NASDAQ:VTYX, VTYX, Medical, Earnings Estimates, Oppenheimer Holdings Inc.",
"snippet": "Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) – Oppenheimer raised their Q3 2022 earnings per share (EPS) estimates for Ventyx Biosciences in a resear...",
"url": "https://www.etfdailynews.com/2022/08/19/ventyx-biosciences-inc-to-post-q3-2022-earnings-of-0-45-per-share-oppenheimer-forecasts-nasdaqvtyx/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/ventyx-biosciences-inc-logo.jpg?v=20211118080627&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:45.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "AIG",
"name": "American International Group, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 27.432674,
"sentiment_score": 0.9022,
"highlights": [
{
"highlight": "American International Group Inc. increased its position in shares of Ventyx Biosciences by 102.3% in the second quarter. American International Group Inc. now owns 10,490 shares of the company’s stock valued at $128,000 after acquiring an additional 5,305 shares during the period. Tokio Marine Asset Management Co.",
"sentiment": 0.9022,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AIG-PA",
"name": "American International Group, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 27.432674,
"sentiment_score": 0.9022,
"highlights": [
{
"highlight": "American International Group Inc. increased its position in shares of Ventyx Biosciences by 102.3% in the second quarter. American International Group Inc. now owns 10,490 shares of the company’s stock valued at $128,000 after acquiring an additional 5,305 shares during the period. Tokio Marine Asset Management Co.",
"sentiment": 0.9022,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JPM",
"name": "JPMorgan Chase & Co.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 34.49165,
"sentiment_score": 0.8402,
"highlights": [
{
"highlight": "Finally, JPMorgan Chase & Co. boosted its holdings in shares of Ventyx Biosciences by 57.8% during the second quarter. JPMorgan Chase & Co. now owns 11,984 shares of the company’s stock worth $147,000 after purchasing an additional 4,391 shares during the period. 62.30% of the stock is owned by hedge funds and other institutional investors.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "c109f9dd-fc00-4efe-bf23-10be288d61c1",
"title": "Clear Secure, Inc. (NYSE:YOU) Expected to Post Q3 2022 Earnings of $0.00 Per Share",
"description": "Read Clear Secure, Inc. (NYSE:YOU) Expected to Post Q3 2022 Earnings of $0.00 Per Share at ETF Daily News",
"keywords": "Clear Secure, NYSE:YOU, YOU, Industrial Product, Earnings Estimates, Telsey Advisory Group",
"snippet": "Clear Secure, Inc. (NYSE:YOU – Get Rating) – Stock analysts at Telsey Advisory Group boosted their Q3 2022 EPS estimates for shares of Clear Secure in a not...",
"url": "https://www.etfdailynews.com/2022/08/19/clear-secure-inc-nyseyou-expected-to-post-q3-2022-earnings-of-0-00-per-share/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/generic-stocks.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:43.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "YOU",
"name": "Clear Secure, Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 150.09393,
"sentiment_score": 0.381411,
"highlights": [
{
"highlight": "Clear Secure, Inc. (NYSE:YOU – Get Rating) – Stock analysts at Telsey Advisory Group boosted their Q3 2022 EPS estimates for shares of Clear Secure in a note issued to investors on Tuesday, August 16th. Telsey Advisory Group analyst D.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "Get Clear Secure alerts:\n\nClear Secure (NYSE:YOU – Get Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.11. Clear Secure had a negative net margin of 15.10% and a negative return on equity of 7.92%.",
"sentiment": -0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Clear Secure Price Performance\n\nInsider Activity\n\nShares of YOU opened at $28.56 on Thursday. The company has a market capitalization of $4.28 billion, a PE ratio of -42.63 and a beta of 1.57. Clear Secure has a one year low of $18.79 and a one year high of $54.27.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Hedge Funds Weigh In On Clear Secure\n\nLarge investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its position in Clear Secure by 6.6% in the fourth quarter.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Clear Secure during the 4th quarter worth approximately $50,000. Envestnet Asset Management Inc. acquired a new stake in Clear Secure in the 4th quarter valued at $486,000. Northern Trust Corp raised its stake in Clear Secure by 35.9% during the fourth quarter.",
"sentiment": 0.8957,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, CIBC Asset Management Inc lifted its holdings in shares of Clear Secure by 9.8% during the fourth quarter. CIBC Asset Management Inc now owns 6,403 shares of the company’s stock valued at $201,000 after acquiring an additional 574 shares during the period. Institutional investors and hedge funds own 62.34% of the company’s stock.",
"sentiment": 0.91,
"highlighted_in": "main_text"
},
{
"highlight": "Clear Secure Company Profile\n\n(Get Rating)\n\nClear Secure, Inc provides a member-centric secure identity platform in the United States. The company's secure identity platform is a multi-layered infrastructure consisting of front-end, including enrollment, verification, and linking.",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "Recommended Stories\n\nReceive News & Ratings for Clear Secure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clear Secure and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.7034,
"highlighted_in": "main_text"
},
{
"highlight": "Clear Secure, Inc. (NYSE:YOU) Expected to Post Q3 2022 Earnings of $0.00 Per Share",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "725ea14b-7f3b-4e81-9bef-bace2e306f97",
"title": "Viracta Therapeutics, Inc. Forecasted to Post Q3 2022 Earnings of ($0.33) Per Share (NASDAQ:VIRX)",
"description": "Read Viracta Therapeutics, Inc. Forecasted to Post Q3 2022 Earnings of ($0.33) Per Share (NASDAQ:VIRX) at ETF Daily News",
"keywords": "Viracta Therapeutics, NASDAQ:VIRX, VIRX, Medical, Earnings Estimates, Oppenheimer Holdings Inc.",
"snippet": "Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating) – Equities researchers at Oppenheimer boosted their Q3 2022 EPS estimates for shares of Viracta Therap...",
"url": "https://www.etfdailynews.com/2022/08/19/viracta-therapeutics-inc-forecasted-to-post-q3-2022-earnings-of-0-33-per-share-nasdaqvirx/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/viracta-therapeutics-inc-logo.jpg?v=20210426074021&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:43.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "VIRX",
"name": "Viracta Therapeutics, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 194.3479,
"sentiment_score": 0.391245,
"highlights": [
{
"highlight": "Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating) – Equities researchers at Oppenheimer boosted their Q3 2022 EPS estimates for shares of Viracta Therapeutics in a report released on Monday, August 15th. Oppenheimer analyst H.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($1.22) per share.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Get Viracta Therapeutics alerts:\n\nSeparately, HC Wainwright reaffirmed a “buy” rating on shares of Viracta Therapeutics in a research report on Thursday, May 12th.\n\nViracta Therapeutics Trading Up 2.2 %\n\nInstitutional Inflows and Outflows\n\nVIRX opened at $4.15 on Thursday.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Viracta Therapeutics has a 52 week low of $1.82 and a 52 week high of $10.12. The business has a fifty day simple moving average of $3.61 and a 200-day simple moving average of $3.17.\n\nSeveral institutional investors and hedge funds have recently added to or reduced their stakes in the company.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "ProShare Advisors LLC purchased a new stake in shares of Viracta Therapeutics during the 4th quarter worth $49,000. Cubist Systematic Strategies LLC acquired a new position in shares of Viracta Therapeutics during the 2nd quarter worth about $52,000.",
"sentiment": 0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Clear Harbor Asset Management LLC purchased a new position in shares of Viracta Therapeutics in the 2nd quarter valued at about $97,000. Veritable L.P. acquired a new stake in shares of Viracta Therapeutics during the 1st quarter worth about $118,000.",
"sentiment": 0.9062,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Ensign Peak Advisors Inc purchased a new stake in Viracta Therapeutics during the fourth quarter worth approximately $221,000. Institutional investors and hedge funds own 56.29% of the company’s stock.",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "Insider Activity at Viracta Therapeutics\n\nIn other Viracta Therapeutics news, CEO Ivor Royston sold 13,162 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $1.90, for a total transaction of $25,007.80.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Viracta Therapeutics Company Profile\n\n(Get Rating)\n\nViracta Therapeutics, Inc, a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Recommended Stories\n\nReceive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.7034,
"highlighted_in": "main_text"
},
{
"highlight": "Viracta Therapeutics, Inc. Forecasted to Post Q3 2022 Earnings of ($0.33) Per Share (NASDAQ:VIRX)",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "a81022e8-a313-403a-84d2-6542cd31803f",
"title": "Q3 2022 EPS Estimates for Royal Bank of Canada Cut by National Bank Financial (TSE:RY)",
"description": "Read Q3 2022 EPS Estimates for Royal Bank of Canada Cut by National Bank Financial (TSE:RY) at ETF Daily News",
"keywords": "Royal Bank of Canada, TSE:RY, RY, Finance, Earnings Estimates, National Bank Financial",
"snippet": "Royal Bank of Canada (TSE:RY – Get Rating) (NYSE:RY) – Stock analysts at National Bank Financial dropped their Q3 2022 EPS estimates for Royal Bank of Canad...",
"url": "https://www.etfdailynews.com/2022/08/19/q3-2022-eps-estimates-for-royal-bank-of-canada-cut-by-national-bank-financial-tsery/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/royal-bank-of-canada-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-08-19T05:16:44.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "RY",
"name": "Royal Bank of Canada",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 142.86618,
"sentiment_score": 0.161609,
"highlights": [
{
"highlight": "Royal Bank of Canada (TSE:RY – Get Rating) (NYSE:RY) – Stock analysts at National Bank Financial dropped their Q3 2022 EPS estimates for Royal Bank of Canada in a note issued to investors on Monday, August 15th. National Bank Financial analyst G.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Get Royal Bank of Canada alerts:\n\nRoyal Bank of Canada (TSE:RY – Get Rating) (NYSE:RY) last announced its earnings results on Thursday, May 26th. The financial services provider reported C$2.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$2.67 by C$0.32.",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Royal Bank of Canada Trading Up 0.4 %\n\nOther research analysts also recently issued reports about the company. Keefe, Bruyette & Woods downgraded Royal Bank of Canada from a “market perform” rating to an “underperform” rating and reduced their price objective for the company from C$132.00 to C$118.00 in a research note on Monday, August 8th.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Argus raised their price target on shares of Royal Bank of Canada to C$157.00 and gave the stock a “buy” rating in a research note on Tuesday, June 7th. Canaccord Genuity Group upped their price objective on shares of Royal Bank of Canada from C$131.50 to C$134.00 in a research note on Friday, May 27th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "CIBC decreased their target price on shares of Royal Bank of Canada from C$149.00 to C$146.00 in a research note on Tuesday, May 17th. Finally, Fundamental Research restated a “buy” rating and issued a C$142.00 price target on shares of Royal Bank of Canada in a research report on Wednesday, June 8th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "According to data from MarketBeat, Royal Bank of Canada has a consensus rating of “Moderate Buy” and an average price target of C$144.67.\n\nTSE:RY opened at C$129.60 on Thursday. The firm has a market cap of C$181.71 billion and a P/E ratio of 11.33. The stock has a 50 day moving average of C$125.28 and a two-hundred day moving average of C$132.58.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Royal Bank of Canada has a 12 month low of C$118.24 and a 12 month high of C$149.60.\n\nInsider Buying and Selling\n\nIn other news, Senior Officer Helena Gottschling sold 405 shares of the firm’s stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of C$126.27, for a total transaction of C$51,140.36.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Royal Bank of Canada Increases Dividend\n\nThe business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 24th. Stockholders of record on Tuesday, July 26th will be issued a $1.28 dividend. This is a positive change from Royal Bank of Canada’s previous quarterly dividend of $1.20.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Royal Bank of Canada Company Profile\n\n(Get Rating)\n\nRoyal Bank of Canada operates as a diversified financial service company worldwide.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Featured Articles\n\nReceive News & Ratings for Royal Bank of Canada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royal Bank of Canada and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Q3 2022 EPS Estimates for Royal Bank of Canada Cut by National Bank Financial (TSE:RY)",
"sentiment": -0.2732,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Example response
marketaux is Incredibly Powerful and Easy-to-Use
Get the latest financial and stock market news from top news sources. Use our API to access clean and relevant financial news and analysis.
Over 200,000 entities tracked every minute
We track over 80 global markets with news from more than 5,000 quality sources in 30+ languages.
Concise analysis of only relevant text allows us to generate superior analytics for stocks and other entities.
VIEW SUPPORTED ENTITIESAdvanced language processing technology
Our NLP technology allows us to identify critical details within news articles.
Our tracked entities include stocks, indices, ETFs, commodities, mutual funds, futures, currencies and crypto, complete with relevant analysis.
GET FREE API KEY
Frequent Asked Questions
Our service is 100% free to use on our free plan - no payment details are required.
Each time the API is used to access financial news or analysis data, 1 API request is added to your daily usage. The number of requests allowed for your account depends on which subscription plan you are on.
Yes, paying annually will provide you 2 months free per year (20% discount). To register for a yearly plan, simply go to our pricing page while logged in and select a plan and you will be prompted to pay monthly or annually.